CDK inhibitors may boost the effectiveness of immune therapy in metastatic breast cancer
A class of drugs that inhibits breast cancer progression when used with hormonal therapy might also boost the effectiveness of immune therapy in cases of recurrent, metastatic breast cancer, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).
Published in the journal
Cell Reports, the findings of the animal study suggest that drugs called CDK4 and CDK6 (CDK4/6) inhibitors might improve the effectiveness of immune therapies for metastatic, estrogen-receptor-positive (ER+) breast cancer.
Recurrent, metastatic breast cancer resists treatment and is usually fatal. These tumors often have low numbers of immune cells in them, which renders immune therapies less effective for the disease. This preclinical study suggests that drugs called CDK4 and CDK6 inhibitors may make immune-cell therapies an effective option for treating recurrent ER-positive metastatic breast cancer.
COLUMBUS, Ohio - A class of drugs that inhibits breast cancer progression when used with hormonal therapy might also boost the effectiveness of immune therapy in cases of recurrent, metastatic breast cancer, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).
Squamous cell carcinoma is the second most common skin cancer in the United States.
In a recent study, researchers exposed mice to UVB radiation and treated them with drugs that target dopamine D2 receptors.
The study showed a reduction of squamous cell carcinomas in the treated mice.
While more research is necessary to confirm the findings, this is the first time a study has shown that activating dopamine receptors may help prevent squamous cell carcinoma.
According to the Skin Cancer Foundation, squamous cell carcinoma is the second most common form of skin cancer in the U.S., behind basal cell carcinoma.
Your Healthy Family: If you re overdue on cancer screenings, it s never too late to act
If you missed your appointments during the pandemic, donât worry about being late. The most important thing is that you go and get screened now. It can save your life.
Posted at 9:51 AM, Apr 27, 2021
and last updated 2021-04-27 12:07:39-04
COLUMBUS, OHIO â As the world looks toward recovery, cancer experts are bracing for a consequence of the pandemic that could impact thousands of lives. The National Cancer Institute estimates that delays in screenings over the past year could account for 10,000 deaths over the next ten years from breast and colorectal cancers alone. Experts at
E-Mail
COLUMBUS, Ohio - A new study of advanced small-cell lung cancer (SCLC) led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified molecular patterns linked to patients developing resistance to certain therapies.
This study, published in the journal
JTO Clinical and Research Reports, examined more than 60 tumors from five patients. OSUCCC - James researchers identified distinct mutational and molecular changes in four SCLC subtypes. The findings provide new insights into the patterns treatment resistance and could offer new targets for the development of more effective immunotherapy and other therapies for advanced SCLC, which progresses quickly and is usually fatal.